Estimation of the efficacy of the measurement of plasma renin activity and direct renin in diagnostics of primary aldosteronism

Goncharov N.P.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Kolesnikova G.S.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Katsiia G.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr MZ CR RF, Moskva

Rogal' E.Iu.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Estimation of the efficacy of the measurement of plasma renin activity and direct renin in diagnostics of primary aldosteronism

Authors:

Goncharov N.P., Kolesnikova G.S., Katsiia G.V., Rogal' E.Iu.

More about the authors

Journal: Problems of Endocrinology. 2012;58(5): 21‑27

Downloaded: 21

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Goncharov NP, Kolesnikova GS, Katsiia GV, Rogal' EIu. Estimation of the efficacy of the measurement of plasma renin activity and direct renin in diagnostics of primary aldosteronism. Problems of Endocrinology. 2012;58(5):21‑27. (In Russ.)

Close metadata

The objective of the present study was to estimate the informative value of the measurements of aldosterone level, direct renin, and plasma renin activity as well as the relationships between these characteristics for differential diagnostics of various forms of hypertension and, first and foremost, of primary aldosteronism. We have examined a total of 162 patients. The results of differential tests were used to allocate them to a few groups including 41 patients presenting with primary aldosteronism, 52 ones with incidentalomas, 26 with essential hypertension, and 43 with various endocrine diseases and normal arterial pressure (control groups). The aldosterone levels, direct renin, and plasma renin activity were measured in blood samples taken in morning hours from the patients in the supine position. The aldosterone to plasma renin activity (A/PRA) and aldosterone to direct renin (A/DR) ratios were calculated. The elevated blood aldosterone level is currently believed to be the principal criterion for primary aldosteronism in the patients suffering arterial hypertension. The RIA technology is the method of choice for the measurement of aldosterone levels. The determination of the A/PR ratio significantly improves the detectability of the disease. The use of direct renin level instead of kinetic renin ensures the high efficacy of screening for primary aldosteronism and its early diagnostics. The cut-off point for the calculation of the A/PRA ratio to differentiate between primary aldosteronism and incidentalomas is 2160 pmol/mcg/hr (sensitivity 100%, specificity 97.8%) in comparison with the analogous cut-off point for the discrimination between primary aldosteronism and endocrine pathology without hypertension is 49 pmol/mU (sensitivity 100%, specificity 95%). The cut-off point for the calculation of the A/PR ratio to differentiate between primary aldosteronism and incidentalomas is 2160 pmol/mcg/hr (sensitivity 89.5%, specificity 99%) in comparison with the analogous cut-off point for the discrimination between primary aldosteronism and endocrine pathology without hypertension is 1432 pmol/mcg/hr (sensitivity 89.5%, specificity 100%). It is concluded that the results of determination of direct renin level in the blood plasma are independent of the endogenous angiotensinogen level, less variable and more reproducible than than the results of the measurement of plasma renin activity. The aldosterone to direct renin ratio may be used for the screening of primary aldosteronism.

Keywords:

aldosterone

direct renin

plasma renin activity

aldosterone to renin ratio

primary aldosteronis

Authors:

Goncharov N.P.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Kolesnikova G.S.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Katsiia G.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr MZ CR RF, Moskva

Rogal' E.Iu.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

List of references:

Hiramatsu K., Yamada T., Yukimura Y., Komiya I., Ichikawa K., Ishihara M., Nagata H., Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma rennin activity. Arch Intern Med 1981; 141: 1489-1593.
Rossi E., Regolisti G., Negro A., Sani C., Davoli S., Perazzolo F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterome to rennin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 10: Pt 1: 896-902.
Lim P.O., Roggers P., Cardale K., Watson A.D., McDonald T.M. Potentially high prevalence of primary aldosterone in a primary-care population. Lancet 1999; 353: 40.
Rossi G.P., Bernini C., Caliumi C., Desideri G., Fabris B., Ferri C., Ganzaroli C., Giacchetti G., Letizia C., Maccario M., Mallamaci F., Manelli M., Matarello M.J., Moretti A., Palumbo G., Parenti G., Porteri E., Semplicini A., Rizzoni D., Rossi E., Boscaro M., Pessina A.C., Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 11: 2293-2300.
Gouli A., Kaltsas G., Tronou A., Marcou A., Androulakis I.I., Radkou D., Vamvakidis K., Zogvarus G., Kontogeorgos G., Chrousos G.P., Piatidis G. High prevalence of automous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011; 41: 11: 1227-1236.
Rossi G.P., Bernini C., Desideri G., Fabris B., Ferri C., Giacchetti G., Letizia C., Maccario M., Manelli M., Matarello M.J., Montemurro D., Palumbo G., Rizzoni D., Rossi E., Pessina F. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 2006; 48: 2: 232-238.
Stowasser M. New perspective on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol 2001; 28: 783-791.
Milliez P., Girard X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248.
Catena C., Colussi G., Nadalini C., Chiuch A., Baroselli S., Lapenna R., Sechi L.A. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 1: 80-85.
Funder J.W., Carey R.M., Fardella C., Gomez-Sanchez C.E., Mantero F., Stowasser M., Young W.J.Jr., Montori V.M. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine, society, clinical, practice guideline. J Clin Endocrinol Metab 2008; 93: 9: 3266-3281.
Rossi G.P., Seccia T.M., Palumbo G., Belfiore A., Bernini G., Caridi G., Desideri G., Fabris B., Ferri C., Giacchetti G., Letizia C., Maccario M., Mallamaci F., Manelli M., Patalano A., Rizzoni D., Rossi E., Pessina A.C., Mantero F. Within-patient reproducibility of the aldosterone:renin ratio in primary aldosteronism. Hypertension 2010; 55: 1: 83-89.
Kestens M.N., Cobold A.C., Volmer M., Koelrts J., Sluiter W.J., Dullaart R.P. Reference value for aldosterone- renin ratio in normotensive individuals and effect of changes in dietary sodium consumption. Clin Chem 2011; 57: 11: 1607-1611.
Rossi G.P., Barisa M., Belfiore A., Desideri G., Ferri C., Letizia C., Maccario M., Morganti A., Palumbo G., Palatano A., Roman E., Seccia T.M., Pessina A.C., Mantero F. The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010; 28: 9: 1899-1992.
Unger N., Lopez Schmidt J., Pitt C., Walz M.K., Philipp T., Mann K., Petersen S. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with the adrenal mass. Eur J Endocrinol 2004; 150: 4: 517-523.
Sau-Cheung Tiu, Cheung-Hei Choi, Chi-Chung Shek, Ying-Wai Ng, Chan F.K.W., Chiu-Ming Ng, Kong A.P.S. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005; 90: 72-78.

Close metadata